Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia

详细信息    查看全文

• 作者：Pallawi Torka¹ ; ^{Pallawi.torka@roswellpark.org" class="auth_mail" title="E-mail the corresponding author} ; Omar Al Ustwani² ; ^{Omarustwani@hotmail.com" class="auth_mail" title="E-mail the corresponding author} ; Meir Wetzler ; Eunice S. Wang³ ; ^{eunice.wang@roswellpark.org" class="auth_mail" title="E-mail the corresponding author} ; Elizabeth A. Griffiths ; ^{elizabeth.griffiths@roswellpark.org" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Oral arsenic trioxide ; Oral arsenicals ; Leukemia ; Hematologic malignancies ; Realgar ; Acute promyelocytic leukemia
• 刊名：Blood Reviews
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：30
• 期：3
• 页码：201-211
• 全文大小：951 K

文摘

Parenteral arsenic trioxide (ATO) has been firmly established as a standard therapy for acute promyelocytic leukemia (APL). Despite widespread use of oral arsenicals in medicine historically, they had disappeared from modern pharmacopeia until oral ATO was redeveloped in Hong Kong in 2000. Since then, over 200 patients with leukemia (predominantly APL) have been treated with oral ATO in Hong Kong and China. Oral arsenic trioxide and other formulations of arsenic appear to have a clinical efficacy comparable to that of IV formulations. These drugs given orally also appear to have a slightly better safety profile, lower operational costs and improved convenience for patients. The clinical experience with oral ATO has previously been reported piecemeal as case series, pilot studies or subgroup analyses rather than in a comprehensive cohort. In this report we attempt to synthesize the published English language literature on oral arsenicals and present the argument for further development of these compounds. Systematic study of this drug with well-designed randomized multi-center clinical trials is needed to accelerate its development and incorporation into clinical practice.